Bio-Rad Laboratories, Inc. Stock NYSE
Stocks
BIO.B
US0905721082
Medical Equipment, Supplies & Distribution
|
Market Closed -
NYSE
04:10:00 2026-10-14 pm EDT
|
5-day change | 1st Jan Change | ||
| 364.15 USD | -0.25% |
|
-0.25% | +17.20% |
| Market Cap | 9.49B 8.46B 7.84B 7.13B 13.37B 900B 13.59B 94B 36.96B 470B 35.61B 34.86B 1,503B | P/E 2026 * |
42.4x | P/E 2027 * | 41.5x |
|---|---|---|---|---|---|
| Enterprise Value | 8.74B 7.79B 7.22B 6.56B 12.32B 829B 12.52B 86.58B 34.05B 433B 32.8B 32.11B 1,385B | EV / Sales 2026 * |
3.4x | EV / Sales 2027 * | 3.25x |
| Free-Float |
60.17% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
NYSE
| BIO.B | Delayed | |
Deutsche Boerse AG
| BUW | Delayed |
Last Transcript: Bio-Rad Laboratories, Inc.
| 1 day | -0.25% | ||
| 1 week | -0.25% | ||
| Current month | -0.25% | ||
| 1 month | -0.25% | ||
| 3 months | +17.71% | ||
| 6 months | +31.46% | ||
| Current year | +17.20% |
| 1 week | 364.15 |  | 364.21 |
| 1 month | 364.15 | | 364.21 |
| Current year | 244.54 | | 365.08 |
| 1 year | 244.54 | | 365.08 |
| 3 years | 0 | | 365.08 |
| 5 years | 0 | | 784.4 |
| 10 years | 0 | | 818.6 |
| Manager | Title | Age | Since |
|---|---|---|---|
Norman Schwartz
CEO | Chief Executive Officer | 76 | 2002-12-31 |
| President | 61 | 2024-09-08 | |
Roop Lakkaraju
DFI | Director of Finance/CFO | 55 | 2024-04-14 |
| Director | Title | Age | Since |
|---|---|---|---|
Norman Schwartz
CHM | Chairman | 76 | 2011-12-31 |
Jeffrey Edwards
BRD | Director/Board Member | 73 | 2017-04-24 |
Gregory Hinckley
BRD | Director/Board Member | 79 | 2017-04-24 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.25% | -0.25% | - | - | 9.51B | |
| -0.79% | +2.20% | -19.04% | +9.03% | 181B | |
| -2.09% | +0.91% | -3.14% | +28.22% | 116B | |
| +1.11% | +5.43% | -20.43% | +11.00% | 113B | |
| -1.52% | +3.61% | -51.34% | -6.22% | 79.83B | |
| -0.27% | +4.60% | +4.72% | +79.05% | 65.06B | |
| -0.14% | +0.83% | +13.02% | +74.65% | 54.35B | |
| -0.53% | +0.98% | +0.87% | -25.92% | 52.23B | |
| -0.81% | +6.08% | -12.53% | +30.57% | 44.15B | |
| -0.07% | +0.07% | +29.10% | -0.07% | 32.47B | |
| Average | -0.54% | +2.99% | -6.53% | +22.26% | 82.07B | |
| Weighted average by Cap. | -0.64% | +2.98% | -11.88% | +20.11% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.57B 2.29B 2.12B 1.93B 3.62B 244B 3.68B 25.45B 10.01B 127B 9.64B 9.44B 407B | 2.62B 2.34B 2.17B 1.97B 3.7B 249B 3.76B 25.99B 10.22B 130B 9.85B 9.64B 416B |
| Net income | 225M 200M 186M 169M 317M 21.32B 322M 2.23B 876M 11.14B 844M 826M 35.62B | 230M 205M 190M 172M 324M 21.78B 329M 2.28B 895M 11.38B 862M 844M 36.39B |
| Net Debt | -749M -668M -618M -562M -1.06B -71.01B -1.07B -7.42B -2.92B -37.12B -2.81B -2.75B -119B | -965M -861M -797M -725M -1.36B -91.53B -1.38B -9.56B -3.76B -47.84B -3.62B -3.55B -153B |
| Date | Price | Change | Volume |
|---|
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- BIO Stock
- BIO.B Stock
Select your edition
All financial news and data tailored to specific country editions
